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Abstract
Purpose: To assess the accuracy of patient repositioning and clinical outcomes of frameless stereotactic
radiosurgery (SRS) for brain metastases using a stereotactic mask fixation system.
Patients and Methods: One hundred two patients treated consecutively with frameless SRS as primary treatment
at University of Rome Sapienza Sant’Andrea Hospital between October 2008 and April 2010 and followed
prospectively were involved in the study. A commercial stereotactic mask fixation system (BrainLab) was used for
patient immobilization. A computerized tomography (CT) scan obtained immediately before SRS was used to
evaluate the accuracy of patient repositioning in the mask by comparing the isocenter position to the isocenter
position established in the planning CT. Deviations of isocenter coordinates in each direction and 3D displacement
were calculated. Overall survival, brain control, and local control were estimated using the Kaplan-Meier method
calculated from the time of SRS.
Results: The mean measured isocenter displacements were 0.12 mm (SD 0.35 mm) in the lateral direction, 0.2 mm (SD
0.4 mm) in the anteroposterior, and 0.4 mm (SD 0.6 mm) in craniocaudal direction. The maximum displacement of 2.1
mm was seen in craniocaudal direction. The mean 3D displacement was 0.5 mm (SD 0.7 mm), being maximum 2.9
mm. The median survival was 15.5 months, and 1-year and 2-year survival rates were 58% and 24%, respectively. Nine
patients recurred locally after SRS, with 1-year and 2-year local control rates of 91% and 82%, respectively. Stable
extracranial disease (P = 0.001) and KPS > 70 (P = 0.01) were independent predictors of survival.
Conclusions: Frameless SRS is an effective treatment in the management of patients with brain metastases. The
presented non-invasive mask-based fixation stereotactic system is associated with a high degree of patient
repositioning accuracy; however, a careful evaluation is essential since occasional errors up to 3 mm may occur.
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Introduction
Stereotactic radiosurgery (SRS) has become increasingly
used for treatment of patients with brain metastases. Its
efficacy when used alone or in combination with whole
brain radiation-therapy (WBRT) has been demonstrated
in several randomized trials and multi-institutional stu-
dies [1-5].
SRS has traditionally been performed using an invasive
fixed head ring that establishes the stereotactic coordi-
nates of the target and allows for an accuracy of immo-
bilization and positioning less than 1 mm during image
acquisition and treatment. More recently, as an alterna-
tive to the invasive patient fixation technique, different
frameless stereotactic systems have been implemented.
A variable positioning accuracy of 1-4 mm has been
reported for frameless stereotactic systems [6-14],
reflecting, at least in part, different methods in patient
fixation, positioning, and assessment of accuracy. The
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target volume for errors in localization and set-up is
essential in order to minimize the potential treatment-
related complications of SRS. Volumes of normal brain
receiving high dose of radiation are in fact predictive of
the development of brain radionecrosis, which is
reported in up to 47% of treated lesions for brain
volumes larger than 10 cc receiving a dose of 12 Gy
[15].
Only limited data on tumor control and target locali-
zation have been provided specifically using linac-based
frameless devices. In this study, we report our clinical
experience in patients with brain metastases with the
use of a commercially available frameless SRS system. In
addition accuracy of target positioning was evaluated
using repeat computed tomography (CT) images.
Patients and Methods
One hundred two patients treated consecutively with
frameless SRS as primary treatment at University of
Rome Sapienza Sant’Andrea Hospital between October
2008 and April 2010 and followed prospectively were
involved in the study. Patient characteristics are listed in
Table 1. Sixty-four patients were treated for 1 metasta-
sis, 24 patients for 2 metastases, and 14 patients for 3
metastases. The median age at the time of SRS was 64
years (range 26-81). The most common histologies were
lung, breast, and melanomas. The most common loca-
tion was parietal lobe followed by frontal and temporal
lobe. According to RTOG recursive partitioning analysis
(RPA) classes for brain metastases, 32 patients (31.5%)
were in RPA Class I, 58 patients (57%) in RPA Class II,
a n d1 2( 1 1 . 5 % )p a t i e n t si nR P AC l a s sI I I .P a t i e n t sw e r e
examined clinically one month after SRS and then every
2 months. MRI was made every 2 months in the first
year after the treatment, and then every 3 months or as
appropriate according to the neurological conditions.
The size of treated lesions was measured in three
dimensions. Complete and partial response were defined
as total radiographic disappearance of lesion or decrease
in tumor volume > 50%. Local progression was defined
as radiographic increase in the size of metastatic lesion.
SRS procedure
After obtained informed consent, patients underwent
contrast-enhanced T1-weighted magnetic resonance
imaging (MRI) (26 cm FOV, 512 × 512 pixel size, 1 mm
slice interval) using a 1.5 Tesla MRI (Siemens Sonata,
Siemens Medical Systems, Erlangen, Germany). Patient
immobilization was achieved by using the commercially
available BrainLab head mask fixation system. In addi-
tion, a mouth bite positioned against the upper denti-
tion attached to the stereotactic frame was applied to
prevent any head tilt movement. The characteristics of
the system have been previously described [16]. Before
the CT localization a localizer box was mounted to the
BrainLAB mask system in order to provide a three-
dimensional (3D) stereotactic coordinate array for target
localization. During the procedure the patient was laid
on the CT couch with the system secured onto a cus-
tom-made platform. CT imaging was performed using
the GE 16-slice scanner. CT (General Electric Medical
System) scanning was done in spiral mode using a pitch
of 0.75, 512 × 512 pixel size, and slices in thickness and
spacing of 1.2 mm acquired throughout the entire cra-
n i u m .T u b ev o l t a g ea n dt u b ep o t e n t i a lw e r es e ta t1 3 0
kV and 300 mA to obtain high quality reconstructed
slices.
The MRI and planning CT datasets were imported
into the BrainLab planning system and stereotactic
coordinates localization were performed by the software
by identifying the location of six localizer rods on the
outside surfaces of the right, left, and anterior walls of
the localizer box. Localization establishes the 3D
Table 1 Summary of tumor charaterictiscs and treatment
parameters of patients treated with radiosurgery
No (%)
Number of patients 102
Median age 64
Sex (F/M) 52/50
No of lesions per patient
1 lesion 64 (63%)
2 lesions 24 (23%)
3 lesions 14 (14%)
Histology
lung 54 (53.5%)
breast 17 (16.5%)
melanoma 14 (13.5%)
others 17(16.5%)
Tumor location
frontal 31 (20%)
parietal 37 (24%)
temporal 30 (19%)
cerebellar 23 (15%)
occipital 26 (17%)
brainstem 7 (5%)
Radiosurgical dose
20 Gy 86 (56%)
18 Gy 44 (28%)
15-16 24 (16%)
Tumor volume (cm
3)
median 1.6
range 0.03-16.3
Treated volume (cm
3)
median 2.2
range 0.2-18.8
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and delivery. The target volume was identified on the
basis of the fused CT and magnetic resonance (MR)
images. The gross tumor volume (GTV) was delineated
as a contrast-enhancing tumor demonstrated on MRI
scans. CTV was considered the same as GTV. The plan-
ning target volume (PTV) was generated by the geo-
metric expansion of GTV plus 1.0 mm. Radiosurgical
dose was 20 Gy for metastases with a volume ≤ 4.3 cm
3
(corresponding to a sphere of 2 cm in diameter), 18 Gy
for metastases with a volume of 4.3-14.1 cm
3,a n d1 6
Gy for metastases with a volume > 14.1 cm
3.D o s e s
were prescribed to the 80-90% isodose line normalized
to the maximum dose. All radiation doses were deliv-
ered in a single fraction with 6-10 noncoplanar dynamic
arcs by using a 6-MV LINAC. Patients with multiple
lesions often underwent treatment in several sessions
over several days.
Immediately before treatment, all patients underwent
CT verification to check the accuracy of isocenter posi-
tion [16]. Firstly, the CT verification set was imported in
the planning system and localized automatically by the
planning software through identification of the stereo-
tactic fiducials in the same way as for planning CT.
Since this step spatially co-registers the stereotactic
coordinate systems of planning CT and verification CT
with the respect to the localizer box, errors in patient
repositioning result in a shift of anatomical isocenter
position. In the second step the planning CT and the
CT verification were fused. Following fusion, anatomy
was co-registered. Since all brain structures were spa-
tially matched, any translation of isocenter position due
to patient repositioning error resulted in a mismatch of
the localizer rods of the localizer box. As consequence,
the 3D stereotactic coordinates of isocenter in the verifi-
cation CT changed accordingly. Finally, the new isocen-
ter coordinates were recorded, and the isocenter shift
between verification and planning CT calculated.
For deviations more than 1 mm the treatment was
replanned on the basis of the new isocenter coordinates.
The whole procedure including verification of isocenter
and replanning lasted less than 8 minutes. During this
time patients fitted with the mask were gently and
slowly moved to a wheelchair and transported from CT
simulation room to the treatment room, and positioned
on the LINAC treatment couch. A post-treatment CT
was performed in 60 patients. Differences in isocenter
position calculated by planning CT and post-treatment
CT fusion were assumed to serve as an indication of the
stability on the patient’s head within the mask during
treatment (intra-fraction motion) and transportation.
Local control and survival from the date of SRS were
calculated using the Kaplan-Meier. Deviations of isocen-
ter coordinates in each direction were measured as
mean ± standard deviation (SD) for all patients. The 3D
displacement determined by the square root of the sum
of squares of the displacements seen in the 3 directions
was calculated. Analysis of subgroups was performed
using the log-rank test, and p = 0.05 was the criterion
for statistical significance.
Results
Accuracy of positioning
The relocation accuracy of the isocenter determined
from CT verification before the treatment is shown in
Table 2. The mean measured isocenter displacements
were 0.12 mm (SD 0.35 mm) in the lateral direction, 0.2
mm (SD 0.4 mm) in the anteroposterior, and 0.4 mm
(SD 0.6 mm) in craniocaudal direction. The maximum
displacement of 2.1 mm was seen in craniocaudal direc-
tion. The mean 3D displacement was 0.5 mm (SD 0.7
mm), being maximum 2.9 mm. A 3D displacement more
than 1 mm was seen in 31 metastases (20%), being more
than 2 mm in 7 metastases (4.5%), and requiring treat-
ment replanning. There was a correlation between devia-
tion of isocenters and the position of metastases in the
brain, with the maximum 3D displacement observed for
metastases located in the cerebellar and frontal lobes
(cerebellar/frontal lobes versus other lobes, p = 0.02).
A post-treatment CT was made in 60 patients (Table
3). Patients fitted with the mask were transported in a
wheelchair from the treatment room to the CT room.
The mean measured isocenter displacements were 0.04
mm (SD 0.14 mm) in the lateral direction, 0.06 mm (SD
0.15 mm) in the anteroposterior direction, and 0.08 mm
(SD 0.2 mm) in craniocaudal direction. The mean 3D
displacement was 0.09 mm (SD 0.28 mm), with the
maximum shift of 0.6 mm.
Quality control procedures at the CT scanner, simula-
tion room and linear accelerator were routinely per-
formed. The accuracy of coincidence of the radiation
isocenter of the treatment unit and the laser-defined room
coordinate system for patient alignment (TC scanner,
simulator and treatment rooms) resulted within 0.8 mm.
Outcome
At a median clinical follow-up of 13.5 months (range 2-
32 months) median survival and brain control were 15.5
Table 2 Accuracy of isocenter relocation at CT
verification
Direction (mm) Mean SD Range
Cranio-caudal 0.4 0.6 -1,2 - 2.1
Medio-lateral 0.12 0.35 -0.9 - 1.4
Anterior-posterior 0.2 0.4 -1,6 - 1.3
3D-displacement 0.5 0.7 0.1-2.9
SD, standard deviation
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year and 2-year survival rates were 67% and 20%, and
respective brain control rates were 50% and 21%. Forty-
three percent of patients succumbed to their extracra-
nial disease and 19% died of progressive intracranial dis-
ease. Data were reported to July 2011. At this time 38%
of patients were alive. Intracranial tumor progression
was observed in 60 patients. The 12-month and 24-
month actuarial rates of developing new brain metas-
tases were 43% and 74%, respectively. Nine patients
recurred locally after SRS. The 1-year and 2-year local
control rates were 91% and 82%, respectively. Salvage
WBRT was applied in 29 patients and further SRS in 30
patients. Thirty-seven metastases (24%) had a complete
response, 59 (38%) had a partial response, and 49 (32%)
remained stable. A clinical neurological improvement of
pre-SRS existing symptoms was recorded in 18 out of
57 patients (31%) following SRS.
Extracranial disease (P = 0.0001), KPS (P = 0.001),
number of metastases (P = 0.01), and RPA class (P =
0.0001) were predictive factors for survival. On multi-
variate analysis stable extracranial disease (P = 0.001)
and KPS > 70 (P = 0.01) were associated with the most
significant survival benefit. Stable extracranial disease (P
= 0.001), KPS > 70 (P = 0.01), and number of metastases
(1 vs > 1, P = 0.001) were significant predictive factors
for brain control; however, only extracranial disease
(P = 0.006) and number of metastases (P = 0.005) were
independent predictors on multivariate analysis. No sig-
nificant prognostic factors were associated with local
control, however there was a trend toward worse con-
trol for melanoma histology (p = 0.15).
Brain radionecrosis, as suggested by MR imaging or
confirmed by histology (n = 9) occurred in 39 (25%) out
of 154 treated lesions. Radionecrosis was symptomatic
in 15 patients, being associated with severe neurological
complications (RTOG Grade 3 and 4) in 7 patients.
Discussion
An essential prerequisite of a frameless stereotactic sys-
tem is that patient immobilization and positioning are
performed with a high degree of accuracy in order to
deliver a safe therapeutic radiation dose as for invasive
frame-based SRS. Different frameless stereotactic sys-
tems, including infrared camera guidance [17], dental
[18-20], implanted fiducial markers [21,22], and mask
fixation system [6-12] have been developed in the last
two decades. In our study using a mask-based stereotac-
tic system we have evaluated the accuracy of isocenter
relocation by repeat CT scans. Mean and SD of displa-
cements for each direction were 0.1 mm (SD 0.35 mm)
in the mediolateral direction, 0.2 mm (SD 0.4 mm) in
the anteroposterior direction, and 0.4 mm (SD 0.6 mm)
in the craniocaudal direction. The mean 3D displace-
ment was 0.5 mm (SD 0.7 mm), being maximum 2.9
mm. Using a similar stereotactic mask fixation system
Wong et al. [11] reported a mean and maximum 3D
displacements at the isocenter evaluated by CT verifica-
tion of 0.7 and 2.5 mm, respectively. Fuss et al [13] in a
series of 22 patients with 43 cranial lesions have
reported a mean 3D target isocenter translation of 1.64
± 0.84 mm, and a maximum dislocation of 3.39 mm,
and similar results have been shown by others [7-10].
In our study repeat CT scan with a thickness of 1.2
mm and standard high-resolution imaging as the matrix
for data acquisition was used to evaluate the accuracy of
isocenter relocation. Analysis of repeated CT datasets
has the advantage of high resolution imaging as com-
pared with portal films [13], although a clear limit of
our procedure is that it can not offer data on real repo-
sitioning accuracy on the treatment table. Recent devel-
opment of image-guided frameless radiosurgery systems
include the use of optical ima g eg u i d a n c ea n dX - r a yt o
evaluate patient repositioning with an accuracy of the
system similar to that reported for invasive frames
[23-28]
An isocenter displacement > 1 mm was found in
approximately 20% of treated lesions, being more than 2
mm in 4.5% of lesions. Although a margin from GTV to
PTV expansion of 3 mm could compensate the inaccu-
racy of positioning reproducibility reported in our series,
Table 3 Mean and standard deviation of isocenter
displacement between CT verification and post-treatment
CT
Direction (mm) Mean SD Range
Cranio-caudal 0.08 0.2 -0.3 - 0.2
Medio-lateral 0.04 0.14 -0.3 - 0.2
Anterior-posterior 0.06 0.15 -0.5 - 0.4
3D-displacement 0.09 0.28 0-0.6
SD, standard deviation
P
r
o
b
a
b
i
l
i
t
y
 
 
     Time (months) 
0
,2
,4
,6
,8
1
0 6 12 18 24 30 36
Overall survival
Brain control 
Local control 
Figure 1 Kaplan-Meier analysis of overall survival, brain
control, and local control.
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high doses (up to 3 times for a lesion of 1.6 cm
3 corre-
sponding to our median tumor volume) and would
likely be unacceptable to avoid serious treatment-related
complications. Thus, in such patients the treatment was
replanned according to new isocenter coordinates as cal-
culated on the basis of CT verification. The time
required for the CT verification was approximately 5
minutes. Another 7 minutes were required for image
transfer, identification of the rods, fusion, recalculation
of isocenter, and replanning. Our verification method
allows us to use an expansion from GTV to PTV of 1
mm during the planning, and this may have important
clinical implications. Several studies have in fact shown
a significant correlation between normal brain volume
receiving a dose of 12 Gy and the development of radio-
necrosis in patients treated with SRS for brain metas-
tases [15,29]. In a series of 310 brain metastases treated
with SRS at our institution the actuarial risk of brain
radionecrosis at 1 year was up to 47% for volumes of
b r a i nl a r g e rt h a n1 0 . 9c m
3 treated at a dose of 12 Gy,
and similar results have been reported by others [29]. In
our current clinical practice the reported procedure per-
mits the use of strict margins for SRS while maintaining
an appropriate coverage of the target, and possibly
avoiding serious treatment-related complications.
The intra-fraction motion is of concern during frame-
less SRS. In order to evaluate the motion of the patient’s
head during the radiosurgical procedure, a post-treat-
ment CT was performed in 60 patients. The differences
in isocenter shift calculated by fusing the verification
CT and post-treatment CT represent an indication of
the accuracy of patient’s head immobilization during
either treatment or transportation from CT couch to
the treatment room. The absence of significant move-
ments during the different steps of the whole procedure
confirms the excellent stability of our mask-based fra-
meless systems and justifies its use for SRS.
Because the ultimate validity of a procedure is mea-
sured in terms of clinical results, we have examined
the local control as the most sensitive clinical outcome
for assessing target accuracy for brain metastases trea-
ted with frameless SRS. The tumor control of 91% at
12 months and 82% at 24 months is in the best range
reported using other frameless stereotactic systems
[30-32], and confirms that frameless SRS is a viable
option for patients with brain metastases with an out-
come similar to that observed following frame-based
SRS [33-37]. Certainly, frameless SRS has several
advantages compared with traditional frame-based
techniques including patient comfort, greater flexibility
in scheduling treatment planning and treatment proce-
dure, possibility to treat multiple lesions in different
days without the need to reapply a head frame, and
the ability to use “multisession radiosurgery” to treat
large lesions.
Our study has some limitations. Patient relocation
evaluated by comparison of localization and verification
CT scans does not include errors which are related to
the treatment unit as laser alignment, machine and
couch accuracy. Thus, although a margin of 1 mm was
associated with an excellent local control and accepata-
ble toxicity, large series and longer follow-up need to
confirm the results reported in our series.
In conclusion, the results presented in this study con-
firm the high accuracy of patient repositioning with the
use of our non-invasive mask-based fixation stereotactic
system. However, a careful evaluation of the reproduci-
bility of patient head position in the mask is essential
since occasional setup errors up to 3 mm may occur.
The promising results in terms of local control and sur-
vival support the use of linac-based frameless SRS as a
common technique in the management of patients with
brain metastases.
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